| INTRODUCTION
We performed tests on DNA sequences from a Chinese newborn with the classic form of maple syrup urine disease and her parents. Compound heterozygous mutations c.1046G>A and c.550delT in the BCKDHB gene had been detected in this patient, and her parents were each heterozygous for one of these mutation.
According to the protein structure-related information in the Protein Data Bank, the novel mutation c.550delT probably altered the secondary structure of E1β protein and reduced the enzymatic activity of E1heterotetramer. The Mutationtaster program predicted c.550delT mutation is "disease-causing."
Maple syrup urine disease (MSUD, OMIM248600) is a rare autosomal recessive inherited metabolic disorder due to the deficiency of branched-chain α-keto acid dehydrogenase (BCKD) complex. This hinders the metabolism of the branched-chain amino acids (BCAAs), resulting in an accumulation of BCAAs and corresponding branched-chain α-keto acids (BCKAs). Thus, it contributes to the MSUD symptoms such as ketoacidosis and hypoglycemia. [1] [2] [3] As a mitochondrial multienzyme complex, BCKD can catalyze the oxidative decarboxylation of BCKAs. 4 BCKD is composed of three catalytic components: a branched-chain α-keto acid decarboxylase (E1) formed by two E1α and two E1β subunits, a dihydrolipoyl transacylase (E2), and a dihydrolipoamide dehydrogenase (E3), encoded by the BCKDHA, BCKDHB, DBT, and DLD genes, respectively.
4,5
The dysfunction of BCKD complex may cause by mutations in these four genes and then inducing the occurrence of MSUD. [6] [7] [8] Based on clinical presentation onset age and residual BCKD complex activity, MUSD can be divided into five forms: classic, intermediate, intermittent, thiamine responsive, and E3 deficient. 9, 10 Approximately 75% of affected individuals has the classic form with less than 2% residual BCKD complex activity and exhibits the most serious phenotype. Generally, patients with classic MSUD appear normal at birth but show poor feeding and lethargy within a week followed by more severe symptoms such as convulsions and progressive brain damage. 6, 9, 11, 12 If untreated, this condition is fatal and most patients often die. 13 Therefore, an early diagnosis and a timely treatment of MSUD patients are crucial to their better prognosis. 1, 14 In this study, compound heterozygotes c.550delT and c.1046G>A in the BCKDHB gene were found in a Chinese neonate with classic form of MSUD. Silico analysis showed the effect of novel mutation c.550delT on the protein structure and function. 
| METHODS

| Clinical data
Our patient was a 12-day-old Han Chinese female infant. Her parents were not consanguineous and did not have MSUD.
Her mother who aborted twice for the embryo stopping development had severe preeclampsia during pregnancy. The baby was delivered by cesarean section and appeared normal at birth. However, she was admitted to our hospital 6 days later due to irregular breathing and poor feeding. Gradually, the infant developed dystonia, lethargy, and a full anterior fontanelle. Plasma amino acid analysis showed elevated BCAAs, with valine at 688.26 μmol/L (normal range 70-300 μmol/L). The total level of leucine, isoleucine, and hydroxyproline was far beyond the normal range (2419.1 μmol/L, normal range 100-330 μmol/L) Additionally, the ratio of the total amount to alanine was nearly 50 times the normal range (49.42, normal range 1-5). Urine organic acid analysis also revealed elevated 2-ketoisovaleric acid, 2-hydroxyisovaleric acid, 2-keto-3-methylpentanoic acid, and 2-ketoisocaproic acid, and there is a maple syrup odor in urine. After differential diagnosis with neonatal encephalopathy, asphyxia, hypoglycemia, status epilepticus, kernicterus, meningitis, and other genetic metabolic diseases caused neonatal encephalopathy, such as urea cycle defects, glycine encephalopathy, propionic acidemia, or methylmalonic academia as well as neonatal sepsis, the girl was diagnosed with a classic form of MSUD and received a dietary protein restriction and vitamin B1 (110 mg/d) supplement. Nevertheless, the patient exhibited a poor response to therapy and presented central respiratory failure and coma. The skull CT and MR were unavailable for the using of life machine, and the patient died at the age of 22 days. The signed informed consents were obtained from her parents, and the study was approved by the Ethics Committee of Qingdao women and children hospital.
| Molecular genetic analysis
Genomic DNA of the patient and her parents was isolated from peripheral blood specimens using QIAamp DNA Blood Mini Kit (Duesseldorf, Germany). Coding of all three genes BCKDHA (NM-000709), BCKDHB (NM-183050), and DBT (NM-001918) was amplified by polymerase chain reaction (PCR) using standard protocol. PCR products were separated and directly sequenced using forward and reverse primers. Analyzed sequences obtained were compared with cDNA sequenced for BCKDHA, BCKDHB, and DBT in GenBank.
| Silico analysis of novel mutation
The related information of secondary structure and functional domain of BCKD E1β protein was extracted from PDB database, and PDB entry codes used were 1X7Y. 15 The
Mutationtaster (http://www.mutationtaster.org/) program was used to predict the total impact of mutations on protein structure and function, and to assess the pathogenicity. 
| Gene mutations detection
No pathogenic mutations were detected in the BCKDHA or DBT gene, but compound heterozygous mutations were identified in the BCKDHB gene. The novel frameshift mutation in exon 5 (c.550delT) resulted in a frameshift of the coding sequence; starting at codon 184 and further leading to multiple changes in the downstream amino acid and a premature stop codon at position 229 (p.S184Pfs*46), the encoded protein is shorter than the wild-type 164 amino acids. The c.1046G>A mutation in exon 10 had been reported previously and led to an amino acid substitution of cysteine to tyrosine at codon 349 (p.C349Y). Direct sequencing analysis of the patient showed the patient's mother carried c.550delT heterozygous mutations, and the father was heterozygous for the c.1046G>A mutation (Figure 1 ).
| The novel mutation c.550delT affects the structure and function of E1β protein
According to the protein structure-related information in the PDB database, the residue p.S184 was located in residues 180-187 of the β-strand. The p.S184Pfs*46 mutation was predicted to alter significantly the secondary structure of E1β protein, including the missing a number of α-helix and β-sheet owing to premature translation termination codons ( Figure 2A) . The residue p.S184 also belonged to the thiamine diphosphate (ThDP)-binding domain. The mutation could markedly change the structure of this domain and the subsequent transketolase C-terminal domain ( Figure 2B ). The Mutationtaster program predicted this frameshift mutation is "disease-causing."
| DISCUSSION
MSUD is a disorder of branched-chain amino acid metabolism caused by mutations in any gene encoding the BCKD complex. There are approximately 29% of mutations occurring in the BCKDHB gene. 16, 17 In this study, compound heterozygous mutations c.1046G>A and c.550delT in the BCKDHB gene had been detected in this patient. Her parents were each heterozygous for one of these mutation, demonstrating that these two mutations were parentally inherited. The newly discovered mutation c.550delT encoding a frameshift and truncating the E1β protein was a "diseasecausing" mutation. E1 protein consisted of α2β2 heterotetramer was a ThDP-dependent enzyme. 18, 19 The structural stabilization of this component of the BCKD complex was depended on the ThDP cofactors that bound to the two active sites at the α-β' and α'-β interfaces, and presence of K + ions. 20 Therefore, the precise spatial correlations of E1 component, including the ThDP-binding domain and K + ion-binding site, are critical to the enzymatic function of E1 component. 15,21 S184 residue was located in a β-strand associated with the K + ion-binding pocket and belonged to ThDP-binding domain. Hence, we speculate the pathogenic p.S184Pfs*46 mutation could reduce the enzymatic activity of E1 tetramer and BCKD complex by destroying the normal E1 protein structure. The missense mutation c.1046G>A resulting in Cys349Tyr amino acid substitution had been previously reported. 3 Yang et al found a Chinese neonate with compound heterozygous mutations c.1046G>A and c.593A>T. Although it was speculated that these two missense mutations hinder the formation of the natural E1 heterotetramer, the mutant E1 complex retained relatively high enzymatic activity, and the patient was diagnosed with intermediate form of MSUD with more slight clinical phenotypes. 3 However, the patient in this study manifested more severe classic form, perhaps due to the presence of pathogenic frameshift p.S184Pfs*46 mutation from her mother's allele. This brings a significant reduction in the function of the E1 protein. Moreover, it is worth mentioning that the patient's mother who carried c.550delT mutation appeared normal, indicating that a heterozygous mutation may not be pathogenic.
In this study, the Mutationtaster program and PDB databases were used to analyze the pathogenicity of the novel mutation. Bioinformatics can be used as a good approach to analyze the effect of novel mutations on protein function if there was no direct evidence to show the pathogenicity of mutations. 22, 23 The combination of clinical data, in silico prediction, and crystal structure analysis has the capacity for providing reliable and timely information on the effects of novel mutations on protein function and clinical phenotypes in patient with MSUD.
In conclusion, we identified a compound heterozygote with a novel mutation c.550delT and a reported mutation c.1046G>A in the BCKDHB gene in a Chinese patient with classic MSUD. Her parents were carriers, and the offspring they have has a 25% chance of being affected, a 50% chance to be a carrier, and a 25% to be neither affected nor a carrier. Therefore, if the mother wants a child with a healthy clinical phenotype, the prenatal diagnosis is recommended for a fetus whose father or mother has a family history of MSUD or with a suspected birth history of MSUD. In addition, neonatal metabolic disease screening is essential for a neonate who is a patient clinically suspected of having MSUD with nonspecific symptoms such as poor sucking response with vomiting, seizures, weak cry, and neurologic deterioration within the first 5-6 days of life. Early diagnosis and intervention can improve the quality of life of neonates.
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